

Literature Survey on Diabetes Treatment

Introduction

Diabetes mellitus, encompassing type 1, type 2, and gestational diabetes, remains a global health challenge due to its rising prevalence and multifaceted complications. Effective treatment strategies are critical not only for glycemic control but also for preventing both microvascular and macrovascular complications. The complexity of diabetes management has driven research toward diverse approaches, including pharmacological innovations, lifestyle interventions, technological integration, and personalized medicine. This literature survey synthesizes recent advances and comprehensive perspectives on diabetes treatment, highlighting pharmacotherapy, lifestyle modifications, emerging technologies, and management of diabetes-related complications.

Pharmacological Approaches in Diabetes Treatment

Traditional and Emerging Drug Therapies

Pharmacotherapy remains a cornerstone of diabetes management, particularly for type 2 diabetes mellitus (T2DM). Metformin continues to be the first-line agent due to its efficacy and safety profile, as supported by Bolen et al. (2007). Sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors constitute the expanding pharmacological arsenal, each targeting different pathophysiological aspects of diabetes (Garber et al., 2019; Garber et al., 2020; Zakir et al., 2023). Notably, GLP-1 mimetics and DPP-4 inhibitors enhance incretin effects, improving insulin secretion with favorable cardiovascular outcomes and minimal hypoglycemia risk (Sun et al., 2017; Mest and Mentlein, 2005; Inzucchi and McGuire, 2008).

Polyagonists, such as tirzepatide, represent a novel class of agents activating multiple incretin receptors (GLP-1 and GIP), offering superior glycemic control and weight loss compared to single-target therapies (Min and Bain, 2020; Disanayake and Somasundaram, 2023). These agents address multiple metabolic pathways simultaneously, potentially improving treatment efficacy while reducing side effects.

Insulin therapy remains essential, especially when oral agents fail or in type 1 diabetes. Advances in insulin formulations, including fast-acting analogues, enable better postprandial glucose control and dosing flexibility (Forst, 2001; Wallia and Molitch, 2014). Switching insulin regimens, such as moving from basal-bolus to co-formulation therapies, may enhance glycemic control and simplify administration (Güneş and Güneş, 2023).

Safety and Drug Interactions

The cardiovascular safety of new antidiabetic drugs is a critical consideration, with regulatory agencies emphasizing rigorous risk assessments to balance efficacy

and safety (Zannad et al., 2016). Drug-drug interactions, particularly involving GLP-1 receptor agonists, are generally minimal, with delayed gastric emptying affecting peak plasma concentrations but not overall drug exposure, reducing concerns over co-administration with oral medications (Calvarysky et al., 2024).

Genetic and Rare Diabetes Forms

Recognition of monogenic diabetes, such as permanent neonatal diabetes mellitus caused by KCNJ11 mutations, underscores the importance of genetic testing for tailored treatment. Some cases respond well to sulfonylureas instead of insulin, highlighting personalized therapy potential (Lachhwani et al., 2023).

Complementary and Alternative Therapies

Medicinal plants, including turmeric, garlic, and Rosella flower, have shown antidiabetic effects in clinical trials within ASEAN populations, though evidence remains limited and standardized research is needed (Salleh et al., 2021). Additionally, yoga therapy as a complementary approach improves glycemic control and psychological well-being through physical and meditative practices (Kumar and Pandey, 2025).

Lifestyle Interventions and Behavioral Management

Dietary Approaches

Dietary modification is a fundamental component of diabetes treatment. Various dietary patterns, including low-carbohydrate, ketogenic, Mediterranean, and low glycemic index diets, have demonstrated efficacy in improving glycemic control and cardiovascular risk factors (Ajala et al., 2013; Jing et al., 2023; Oh et al., 2024). Low-carbohydrate and ketogenic diets, in particular, show promise in reducing HbA1c and medication dependence, sometimes achieving remission in T2DM (Oh et al., 2024). The DIAMOND trial explores a low-energy, low-carbohydrate dietary intervention delivered in primary care, aiming to induce remission and reduce cardiovascular risk (Scragg et al., 2023; Morris et al., 2019).

Physical Activity and Exercise

Exercise is critical for glucose management, especially in type 1 diabetes, where tailored insulin and carbohydrate adjustments prevent hypoglycemia during physical activity (Moser and Thurm, 2024). Resistance training and aerobic exercise improve insulin sensitivity and muscle function, particularly important in elderly patients with sarcopenia and T2DM (Hou et al., 2024).

Sleep and Psychosocial Factors

Emerging evidence highlights sleep's role in diabetes management. Sleep quantity, quality, and timing influence glycemic control and cardiovascular risk, warranting

integration of sleep assessment into diabetes care (Henson et al., 2024; Alnaji et al., 2016). Moreover, family and partner support significantly enhance adherence to lifestyle and medication regimens, improving glycemic outcomes and quality of life (Gupta et al., 2019).

Lifestyle Interventions in Special Populations

Lifestyle interventions also prevent gestational diabetes mellitus (GDM) and adverse pregnancy outcomes in high-risk women through dietary guidance, weight management, and health education (Xu et al., 2023; Nakshine and Jogdand, 2023). In Asian populations, culturally tailored community-based programs effectively reduce T2DM incidence, addressing ethnic-specific risk profiles (Modesti et al., 2016).

Technological and Personalized Medicine Advances

Artificial Intelligence and Machine Learning

AI and machine learning applications are increasingly explored for diabetes treatment optimization. Jamil et al. (2024) discuss AI/ML’s role in early diagnosis and management of diabetic cardiomyopathies, enhancing classification and therapeutic strategies. Similarly, large language models fine-tuned on electronic health records can generate personalized outpatient treatment recommendations, improving clinical decision-making efficiency while recognizing limitations that require clinical oversight (Yang et al., 2023).

Electronic Medical Records and Clinical Trials

Utilizing electronic medical records (EMR) facilitates efficient recruitment for diabetes treatment trials, enabling targeted prescreening and enhancing minority participation, as demonstrated in the LIFT Diabetes trial (Effoe et al., 2016).

Medication Adherence and Patient Perceptions

Medication adherence remains a challenge, influenced by patient perceptions of side effects, treatment burden, and psychosocial factors. Addressing these through patient-centered communication improves adherence and outcomes (McSharry et al., 2016; Melzer et al., 2015).

Management of Diabetes-Related Complications

Cardiovascular Complications

Cardiovascular disease is a leading cause of morbidity and mortality in diabetes. Effective treatment integrates glycemic control with management of blood pressure, lipids, and platelet function (Zakir et al., 2023). Pharmacological agents like GLP-1 receptor agonists and SGLT2 inhibitors provide cardiovascular benefits beyond glucose lowering (Garber et al., 2020; Zakir et al., 2023).

Microvascular Complications and Intensive Glycemic Control

Intensive glycemic control reduces microvascular complications such as retinopathy, nephropathy, and neuropathy in both type 1 and type 2 diabetes (Nathan et al., 1993; Reichard et al., 1993; Boer et al., 2014; Holman et al., 2008; Patel et al., 2008). Early and sustained glucose control confers long-term benefits, including reduced albuminuria and improved renal outcomes (Boer et al., 2014).

Sarcopenia and Muscle Health

Sarcopenia, prevalent in elderly T2DM patients, exacerbates metabolic control and quality of life. Comprehensive management includes strict glycemic control, nutritional supplementation (protein, vitamin D, omega-3 fatty acids), and resistance exercise, with consideration of antidiabetic drug effects on muscle mass (Hou et al., 2024).

Hypoglycemia and Safety Monitoring

Standardized reporting of hypoglycemia, especially glucose levels below 3.0 mmol/L, is vital in clinical trials and practice to ensure patient safety and optimize treatment regimens (ADA and EASD, 2016).

Conclusion

Diabetes treatment has evolved into a multifaceted discipline encompassing pharmacological innovations, lifestyle modifications, technological integration, and personalized care. Advances in drug therapies, including polyagonists and incretin-based agents, offer improved efficacy and cardiovascular benefits. Lifestyle interventions, particularly tailored dietary and exercise programs, remain foundational, with growing recognition of sleep and psychosocial factors. The integration of AI and EMR systems holds promise for personalized management and enhanced clinical trial recruitment. Effective management of diabetes-related complications through early intensive glycemic control and comprehensive cardiovascular risk reduction is essential. Future research should focus on optimizing personalized treatment strategies, validating emerging technologies, and addressing adherence challenges to improve long-term outcomes for diverse diabetic populations.

References

Ajala, O., English, P., & Pinkney, J. (2013). Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. *American Journal of Clinical Nutrition*.

American Diabetes Association & European Association for the Study of Diabetes. (2016). Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: A joint position statement. *Diabetes Care*.

- Boer, I., Sun, W., Gao, X., Cleary, P., Lachin, J., Molitch, M., Steffes, M., & Zinman, B. (2014). Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the DCCT and EDIC study. *The Lancet Diabetes and Endocrinology*.
- Bolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E., & Brancati, F. (2007). Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. *Annals of Internal Medicine*.
- Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. (2024). Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: A systematic review. *Drug Safety*.
- Dissanayake, H., & Somasundaram, N. (2023). Polyagonists in type 2 diabetes management. *Current Diabetes Reports*.
- Effoe, V., Katula, J., Kirk, J., Pedley, C., Bollhalter, L., Brown, W., Savoca, M., Jones, S., Baek, J., Bertoni, A., & the Team. (2016). The use of electronic medical records for recruitment in clinical trials: findings from the Lifestyle Intervention for Treatment of Diabetes trial. *Trials*.
- Forst, T. (2001). New drugs for diabetes treatment. Fast-acting insulin analogues. *Pharmazie in unserer Zeit*.
- Garber, A., Abrahamson, M., Barzilay, J., Blonde, L., Bloomgarden, Z., Bush, M., Dagogo-Jack, S., DeFronzo, R., Einhorn, D., Fonseca, V., Garber, J., Garvey, W., Grunberger, G., Handelsman, Y., Hirsch, I., Jellinger, P., McGill, J., Mechanick, J., Rosenblit, P., & Umpierrez, G. (2019). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary. *Endocrine Practice*.
- Garber, A., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M., Barzilay, J., Blonde, L., Bush, M., DeFronzo, R., Garber, J., Garvey, W., Hirsch, I., Jellinger, P., McGill, J., Mechanick, J., Perreault, L., Rosenblit, P., Samson, S., & Umpierrez, G. (2020). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. *Endocrine Practice*.
- Güneş, E., & Güneş, M. (2023). Efficacy of switching from basal-bolus insulin therapy to twice-daily insulin degludec/insulin aspart co-formulation plus insulin aspart in patients with poorly controlled type 2 diabetes. *European Review for Medical and Pharmacological Sciences*.
- Gupta, L., Khandelwal, D., Lal, P., Gupta, Y., Kalra, S., & Dutta, D. (2019). Factors determining the success of therapeutic lifestyle interventions in diabetes – Role of partner and family support. *European Endocrinology*.

- Henson, J., Covenant, A., Hall, A., Herring, L., Rowlands, A., Yates, T., & Davies, M. (2024). Waking up to the importance of sleep in type 2 diabetes management: A narrative review. *Diabetes Care*.
- Hou, Y., Xiang, J., Wang, B., Duan, S., Song, R., Zhou, W., Tan, S., & He, B. (2024). Pathogenesis and comprehensive treatment strategies of sarcopenia in elderly patients with type 2 diabetes mellitus. *Frontiers in Endocrinology*.
- Inzucchi, S., & McGuire, D. (2008). New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. *Circulation*.
- Jamil, G., Yerra, S., Tantray, J., & Asimuddim, M. (2024). Tackling two titans: Diabetes treatment strategies and their influence on cardiomyopathies. *Unknown Venue*.
- Jing, T., Zhang, S., Bai, M., Chen, Z., Gao, S., Li, S., & Zhang, J. (2023). Effect of dietary approaches on glycemic control in patients with type 2 diabetes: A systematic review with network meta-analysis of randomized trials. *Nutrients*.
- Kumar, R., & Pandey, R. (2025). Yoga therapy for diabetes management: A comprehensive review. *International Journal For Multidisciplinary Research*.
- Lachhwani, H., Kumar, D., Ishpujani, S., Pande, A., & Chandra, K. (2023). Rare case of permanent neonatal diabetes mellitus (monogenic diabetes) with late childhood presentation not requiring insulin therapy. *Global Journal For Research Analysis*.
- Melzer, A., Uman, J., & Au, D. (2015). Adherence to oral medications for hypertension and diabetes in veterans with comorbid airflow limitation. *Unknown Venue*.
- Min, T., & Bain, S. (2020). The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials. *Diabetes Therapy*.
- Modesti, P., Galanti, G., Calà, P., & Calabrese, M. (2016). Lifestyle interventions in preventing new type 2 diabetes in Asian populations. *Internal and Emergency Medicine*.
- Moser, O., & Thurm, U. (2024). Exercise and type 1 diabetes: treatment strategies and glucose management. *Die Diabetologie*.
- Nakshine, V., & Jogdand, S. (2023). A comprehensive review of gestational diabetes mellitus: Impacts on maternal health, fetal development, childhood outcomes, and long-term treatment strategies. *Cureus*.
- Nathan, D., Genuth, S., Lachin, J., Cleary, P., Crofford, O., Davis, M., Rand, L., & Siebert, C. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *New England Journal of Medicine*.

- Oh, R., Murphy, K., Jenks, C., Lopez, K., Patel, M., Scotland, E., & Khanna, M. (2024). Low-carbohydrate and ketogenic dietary patterns for type 2 diabetes management. *Federal Practitioner*.
- Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Marre, M., Cooper, M., Glasziou, P., Grobbee, D., Hamet, P., Harrap, S., Heller, S., Liu, L., Mancia, G., Mogensen, C., Pan, C., Poulter, N., Rodgers, A., Williams, B., Bompoint, S., Galan, B., Joshi, R., & Travert, F. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *New England Journal of Medicine*.
- Reichard, P., Nilsson, B., & Rosenqvist, U. (1993). The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. *New England Journal of Medicine*.
- Salleh, N., Zulkipli, I., Yasin, H., Ja'afar, F., Ahmad, N., Wan Ahmad, S., & Ahmad, S. (2021). Systematic review of medicinal plants used for treatment of diabetes in human clinical trials: An ASEAN perspective. *Evidence-Based Complementary and Alternative Medicine*.
- Scragg, J., Morris, E., Wane, S., Noreik, M., Jerome, D., Yu, L., Galal, U., Dyson, P., Tan, G., Fox, R., Breeze, P., Thomas, C., Jebb, S., & Aveyard, P. (2023). Dietary approaches to the management of type 2 diabetes (DIAMOND) in primary care: A protocol for a cluster randomised trial. *Contemporary Clinical Trials*.
- Sun, X., Wang, Y., & Li, M. (2017). Advances in new drugs for diabetes treatment: GLP-1 mimetics and DPP-4 inhibitors. *Unknown Venue*.
- Thorkelson, S., & Anderson, K. (2016). Oral medications for diabetes in pregnancy: Use in a rural population. *Diabetes Spectrum*.
- Yang, H., Li, J., Liu, S., du, L., Liu, X., Huang, Y., Shi, Q., & Liu, J. (2023). Exploring the potential of large language models in personalized diabetes treatment strategies. *medRxiv*.
- Zakir, M., Ahuja, N., Surksha, M., Sachdev, R., Kalariya, Y., Nasir, M., Kashif, M., Shahzeen, F., Tayyab, A., Khan, M., Junejo, M., Kumar, F.N.U., Varrassi, G., Kumar, S., Khatri, M., & Mohamad, T. (2023). Cardiovascular complications of diabetes: From microvascular to macrovascular pathways. *Cureus*.
- Zannad, F., Stough, W., Lipicky, R., Tamargo, J., Bakris, G., Borer, J., García, M., Hadjadj, S., Koenig, W., Kupfer, S., McCullough, P., Mosenzon, O., Pocock, S., Scheen, A., Sourij, H., Schueren, B., Stahre, C., White, W., & Calvo, G. (2016). Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. *Unknown Venue*.